Afam Capital Inc. raised its holdings in Johnson & Johnson (NYSE:JNJ) by 3.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 65,803 shares of the company’s stock after buying an additional 2,113 shares during the quarter. Johnson & Johnson comprises 1.1% of Afam Capital Inc.’s holdings, making the stock its 16th largest position. Afam Capital Inc.’s holdings in Johnson & Johnson were worth $8,705,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in JNJ. Harding Loevner LP acquired a new position in shares of Johnson & Johnson in the second quarter valued at about $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its holdings in shares of Johnson & Johnson by 29.9% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after purchasing an additional 200 shares during the period. Lenox Wealth Advisors Inc. increased its holdings in shares of Johnson & Johnson by 0.6% in the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after purchasing an additional 5 shares during the period. IHT Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 46.4% in the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after purchasing an additional 3,467 shares during the period. Finally, Mountain Capital Investment Advisors Inc acquired a new position in shares of Johnson & Johnson in the second quarter valued at about $124,000. Institutional investors own 65.89% of the company’s stock.

Shares of Johnson & Johnson (JNJ) traded up $0.29 on Thursday, reaching $142.89. The company’s stock had a trading volume of 6,118,300 shares, compared to its average volume of 5,871,992. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. Johnson & Johnson has a one year low of $110.76 and a one year high of $144.35. The firm has a market capitalization of $383,702.22, a price-to-earnings ratio of 20.00, a P/E/G ratio of 2.90 and a beta of 0.80.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The company had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. During the same period last year, the company earned $1.68 earnings per share. Johnson & Johnson’s quarterly revenue was up 10.3% compared to the same quarter last year. analysts anticipate that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th were issued a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 2.35%. The ex-dividend date was Monday, November 27th. Johnson & Johnson’s payout ratio is currently 58.33%.

A number of brokerages have recently weighed in on JNJ. J P Morgan Chase & Co increased their price objective on Johnson & Johnson from $140.00 to $148.00 and gave the company an “overweight” rating in a report on Wednesday, August 16th. Vetr lowered Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 target price on the stock. in a report on Monday, September 18th. BMO Capital Markets raised their target price on Johnson & Johnson to $161.00 and gave the stock an “outperform” rating in a report on Tuesday. Stifel Nicolaus raised their target price on Johnson & Johnson from $140.00 to $142.00 and gave the stock a “hold” rating in a report on Wednesday, October 18th. Finally, Citigroup raised their target price on Johnson & Johnson from $140.00 to $149.00 and gave the stock a “buy” rating in a report on Monday, October 23rd. Four analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have issued a buy rating to the company’s stock. Johnson & Johnson has an average rating of “Hold” and an average price target of $145.04.

ILLEGAL ACTIVITY NOTICE: This article was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.watchlistnews.com/johnson-johnson-jnj-shares-bought-by-afam-capital-inc/1763824.html.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.